AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. TECH
  4. [Form 4] Bio-Techne Corp. Insider Trading Activity

[Form 4] Bio-Techne Corp. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Very Negative)
Form Type
4
Rhea-AI Filing Summary

T-Mobile US, Inc. (TMUS) 鈥� Form 4 insider transaction. President of the Business Group, Callie R. Field, reported the sale of 12,300 common shares on 07/29/2025 under transaction code 鈥淪.鈥� The weighted-average sale price was $240.80 per share (range: $240.79-$240.87). After the sale, Field directly owns 110,891.114 shares of TMUS common stock. No derivative security activity or Rule 10b5-1 trading plan disclosure was indicated. The filing was signed by Attorney-in-Fact Frederick Williams on 07/31/2025.

The transaction reduces Field鈥檚 direct holdings by roughly 10% versus the pre-sale balance (123,191.114 shares) but leaves a substantial remaining position. No accompanying narrative explains motive or use of proceeds, and there were no other simultaneous insider transactions disclosed.

T-Mobile US, Inc. (TMUS) 鈥� Transazione interna Form 4. Callie R. Field, Presidente del Business Group, ha comunicato la vendita di 12.300 azioni ordinarie il 29/07/2025 con codice transazione 鈥淪.鈥� Il prezzo medio ponderato di vendita 猫 stato di 240,80 $ per azione (intervallo: 240,79-240,87 $). Dopo la vendita, Field detiene direttamente 110.891,114 azioni del capitale ordinario TMUS. Non sono state indicate attivit脿 su titoli derivati n茅 piani di negoziazione secondo la regola 10b5-1. La dichiarazione 猫 stata firmata dall鈥橝vvocato Delegato Frederick Williams il 31/07/2025.

La transazione riduce la partecipazione diretta di Field di circa il 10% rispetto al saldo pre-vendita (123.191,114 azioni), mantenendo comunque una posizione significativa. Non 猫 stata fornita alcuna spiegazione riguardo al motivo o all鈥檜tilizzo del ricavato, n茅 sono state divulgate altre transazioni interne simultanee.

T-Mobile US, Inc. (TMUS) 鈥� Transacci贸n interna Formulario 4. Callie R. Field, Presidenta del Grupo de Negocios, report贸 la venta de 12,300 acciones comunes el 29/07/2025 bajo el c贸digo de transacci贸n 鈥淪.鈥� El precio promedio ponderado de venta fue de $240.80 por acci贸n (rango: $240.79-$240.87). Despu茅s de la venta, Field posee directamente 110,891.114 acciones comunes de TMUS. No se indic贸 actividad con valores derivados ni plan de negociaci贸n conforme a la regla 10b5-1. La presentaci贸n fue firmada por el Apoderado Frederick Williams el 31/07/2025.

La transacci贸n reduce la tenencia directa de Field en aproximadamente un 10% respecto al saldo previo a la venta (123,191.114 acciones), pero mantiene una posici贸n sustancial. No se proporcion贸 ninguna explicaci贸n sobre el motivo o uso de los ingresos, ni se divulgaron otras transacciones internas simult谩neas.

T-Mobile US, Inc. (TMUS) 鈥� Form 4 雮措秬鞛� 瓯半灅 氤搓碃. 牍勳雼堨姢 攴鸽９ 靷灔鞚� Callie R. Field臧� 2025雲� 7鞗� 29鞚� 瓯半灅 旖旊摐 鈥淪鈥濍 12,300欤� 氤错喌欤� 毵る弰毳� 氤搓碃頄堨姷雼堧嫟. 臧�欷戫弶攴� 毵る弰 臧�瓴╈潃 欤茧嫻 $240.80 (氩旍渼: $240.79-$240.87)鞚挫棃鞀惦媹雼�. 毵る弰 頉� Field電� TMUS 氤错喌欤� 110,891.114欤�毳� 歆侅爲 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 韺岇儩靸來拡 瓯半灅雮� Rule 10b5-1 瓯半灅 瓿勴殟 瓿店皽電� 鞐嗢棃鞀惦媹雼�. 鞁犼碃靹滊姅 2025雲� 7鞗� 31鞚� 雽�毽澑 Frederick Williams臧� 靹滊獏頄堨姷雼堧嫟.

鞚措矆 瓯半灅搿� Field鞚� 歆侅爲 氤挫湢 欤检嫕鞚� 毵る弰 鞝� 鞛旍暋(123,191.114欤�) 雽�牍� 鞎� 10% 臧愳唽頄堨溂雮�, 鞐爠頌� 靸侂嫻頃� 歆�攵勳潉 鞙犾頃橁碃 鞛堨姷雼堧嫟. 瓯半灅 霃欔赴雮� 靾橃澋 靷毄鞐� 雽�頃� 靹る獏鞚� 鞐嗢溂氅�, 霃欖嫓 雮措秬鞛� 瓯半灅霃� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

T-Mobile US, Inc. (TMUS) 鈥� Transaction d鈥檌niti茅 Formulaire 4. Callie R. Field, Pr茅sidente du Business Group, a d茅clar茅 la vente de 12 300 actions ordinaires le 29/07/2025 sous le code de transaction 芦 S 禄. Le prix moyen pond茅r茅 de vente 茅tait de 240,80 $ par action (fourchette : 240,79-240,87 $). Apr猫s la vente, Field d茅tient directement 110 891,114 actions ordinaires de TMUS. Aucune activit茅 sur titres d茅riv茅s ni plan de n茅gociation selon la r猫gle 10b5-1 n鈥檃 茅t茅 signal茅e. Le d茅p么t a 茅t茅 sign茅 par le mandataire Frederick Williams le 31/07/2025.

La transaction r茅duit la d茅tention directe de Field d鈥檈nviron 10 % par rapport au solde avant la vente (123 191,114 actions) tout en conservant une position substantielle. Aucun commentaire explicatif sur la motivation ou l鈥檜tilisation des fonds n鈥檃 茅t茅 fourni, et aucune autre transaction d鈥檌niti茅 simultan茅e n鈥檃 茅t茅 divulgu茅e.

T-Mobile US, Inc. (TMUS) 鈥� Form 4 Insider-Transaktion. Callie R. Field, Pr盲sidentin der Business Group, meldete am 29.07.2025 den Verkauf von 12.300 Stammaktien unter Transaktionscode 鈥濻鈥�. Der gewichtete Durchschnittspreis lag bei 240,80 $ pro Aktie (Spanne: 240,79鈥�240,87 $). Nach dem Verkauf besitzt Field direkt 110.891,114 TMUS-Stammaktien. Es wurden keine Aktivit盲ten mit Derivaten oder Offenlegungen eines Rule 10b5-1 Handelsplans angegeben. Die Meldung wurde am 31.07.2025 vom Bevollm盲chtigten Frederick Williams unterzeichnet.

Die Transaktion verringert Fields Direktbestand um etwa 10 % gegen眉ber dem Bestand vor dem Verkauf (123.191,114 Aktien), l盲sst aber eine betr盲chtliche Restposition bestehen. Es wurde kein erl盲uternder Kommentar zum Motiv oder zur Verwendung der Erl枚se gegeben, und es wurden keine weiteren gleichzeitigen Insider-Transaktionen offengelegt.

Positive
  • None.
Negative
  • President Callie R. Field sold 12,300 shares (~$3 million), reducing her holdings by ~10%, which can be viewed as a modestly negative insider-sentiment signal.

Insights

TL;DR: Officer sold ~10% of holdings; modestly negative governance signal.

Insider sales by senior executives often draw scrutiny because they can hint at internal views on valuation or future performance. The 12.3k-share sale is sizable in dollar terms (~$3.0 million) but leaves Field with >110k shares, suggesting continued alignment with shareholders. Absence of a 10b5-1 plan and the concentration within a single day slightly elevate sentiment risk, though the transaction alone is not alarming given the remaining stake and lack of broader insider selling.

TL;DR: Transaction is small relative to TMUS float; market impact immaterial.

TMUS averages multi-million-share daily volume; 12,300 shares is negligible for liquidity and unlikely to move price. Nevertheless, insider direction matters to sentiment, and this is the first reported sale by Field in 2025. I view the filing as not impactful to valuation models or target price, but I would monitor for additional selling patterns from multiple insiders before adjusting position weights.

T-Mobile US, Inc. (TMUS) 鈥� Transazione interna Form 4. Callie R. Field, Presidente del Business Group, ha comunicato la vendita di 12.300 azioni ordinarie il 29/07/2025 con codice transazione 鈥淪.鈥� Il prezzo medio ponderato di vendita 猫 stato di 240,80 $ per azione (intervallo: 240,79-240,87 $). Dopo la vendita, Field detiene direttamente 110.891,114 azioni del capitale ordinario TMUS. Non sono state indicate attivit脿 su titoli derivati n茅 piani di negoziazione secondo la regola 10b5-1. La dichiarazione 猫 stata firmata dall鈥橝vvocato Delegato Frederick Williams il 31/07/2025.

La transazione riduce la partecipazione diretta di Field di circa il 10% rispetto al saldo pre-vendita (123.191,114 azioni), mantenendo comunque una posizione significativa. Non 猫 stata fornita alcuna spiegazione riguardo al motivo o all鈥檜tilizzo del ricavato, n茅 sono state divulgate altre transazioni interne simultanee.

T-Mobile US, Inc. (TMUS) 鈥� Transacci贸n interna Formulario 4. Callie R. Field, Presidenta del Grupo de Negocios, report贸 la venta de 12,300 acciones comunes el 29/07/2025 bajo el c贸digo de transacci贸n 鈥淪.鈥� El precio promedio ponderado de venta fue de $240.80 por acci贸n (rango: $240.79-$240.87). Despu茅s de la venta, Field posee directamente 110,891.114 acciones comunes de TMUS. No se indic贸 actividad con valores derivados ni plan de negociaci贸n conforme a la regla 10b5-1. La presentaci贸n fue firmada por el Apoderado Frederick Williams el 31/07/2025.

La transacci贸n reduce la tenencia directa de Field en aproximadamente un 10% respecto al saldo previo a la venta (123,191.114 acciones), pero mantiene una posici贸n sustancial. No se proporcion贸 ninguna explicaci贸n sobre el motivo o uso de los ingresos, ni se divulgaron otras transacciones internas simult谩neas.

T-Mobile US, Inc. (TMUS) 鈥� Form 4 雮措秬鞛� 瓯半灅 氤搓碃. 牍勳雼堨姢 攴鸽９ 靷灔鞚� Callie R. Field臧� 2025雲� 7鞗� 29鞚� 瓯半灅 旖旊摐 鈥淪鈥濍 12,300欤� 氤错喌欤� 毵る弰毳� 氤搓碃頄堨姷雼堧嫟. 臧�欷戫弶攴� 毵る弰 臧�瓴╈潃 欤茧嫻 $240.80 (氩旍渼: $240.79-$240.87)鞚挫棃鞀惦媹雼�. 毵る弰 頉� Field電� TMUS 氤错喌欤� 110,891.114欤�毳� 歆侅爲 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 韺岇儩靸來拡 瓯半灅雮� Rule 10b5-1 瓯半灅 瓿勴殟 瓿店皽電� 鞐嗢棃鞀惦媹雼�. 鞁犼碃靹滊姅 2025雲� 7鞗� 31鞚� 雽�毽澑 Frederick Williams臧� 靹滊獏頄堨姷雼堧嫟.

鞚措矆 瓯半灅搿� Field鞚� 歆侅爲 氤挫湢 欤检嫕鞚� 毵る弰 鞝� 鞛旍暋(123,191.114欤�) 雽�牍� 鞎� 10% 臧愳唽頄堨溂雮�, 鞐爠頌� 靸侂嫻頃� 歆�攵勳潉 鞙犾頃橁碃 鞛堨姷雼堧嫟. 瓯半灅 霃欔赴雮� 靾橃澋 靷毄鞐� 雽�頃� 靹る獏鞚� 鞐嗢溂氅�, 霃欖嫓 雮措秬鞛� 瓯半灅霃� 氤搓碃霅橃 鞎婌晿鞀惦媹雼�.

T-Mobile US, Inc. (TMUS) 鈥� Transaction d鈥檌niti茅 Formulaire 4. Callie R. Field, Pr茅sidente du Business Group, a d茅clar茅 la vente de 12 300 actions ordinaires le 29/07/2025 sous le code de transaction 芦 S 禄. Le prix moyen pond茅r茅 de vente 茅tait de 240,80 $ par action (fourchette : 240,79-240,87 $). Apr猫s la vente, Field d茅tient directement 110 891,114 actions ordinaires de TMUS. Aucune activit茅 sur titres d茅riv茅s ni plan de n茅gociation selon la r猫gle 10b5-1 n鈥檃 茅t茅 signal茅e. Le d茅p么t a 茅t茅 sign茅 par le mandataire Frederick Williams le 31/07/2025.

La transaction r茅duit la d茅tention directe de Field d鈥檈nviron 10 % par rapport au solde avant la vente (123 191,114 actions) tout en conservant une position substantielle. Aucun commentaire explicatif sur la motivation ou l鈥檜tilisation des fonds n鈥檃 茅t茅 fourni, et aucune autre transaction d鈥檌niti茅 simultan茅e n鈥檃 茅t茅 divulgu茅e.

T-Mobile US, Inc. (TMUS) 鈥� Form 4 Insider-Transaktion. Callie R. Field, Pr盲sidentin der Business Group, meldete am 29.07.2025 den Verkauf von 12.300 Stammaktien unter Transaktionscode 鈥濻鈥�. Der gewichtete Durchschnittspreis lag bei 240,80 $ pro Aktie (Spanne: 240,79鈥�240,87 $). Nach dem Verkauf besitzt Field direkt 110.891,114 TMUS-Stammaktien. Es wurden keine Aktivit盲ten mit Derivaten oder Offenlegungen eines Rule 10b5-1 Handelsplans angegeben. Die Meldung wurde am 31.07.2025 vom Bevollm盲chtigten Frederick Williams unterzeichnet.

Die Transaktion verringert Fields Direktbestand um etwa 10 % gegen眉ber dem Bestand vor dem Verkauf (123.191,114 Aktien), l盲sst aber eine betr盲chtliche Restposition bestehen. Es wurde kein erl盲uternder Kommentar zum Motiv oder zur Verwendung der Erl枚se gegeben, und es wurden keine weiteren gleichzeitigen Insider-Transaktionen offengelegt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hippel James
(Last) (First) (Middle)
614 MCKINLEY PLACE NE
(Street)
MINNEAPOLIS MN 55413
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO
3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/29/2025 M 168,620 A $44.33 275,230 D
Common Stock 07/29/2025 F 147,431 D $58.55 127,799 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $44.33 07/29/2025 M 168,620 (1) 08/08/2025 Common Stock 168,620 $0 0 D
Stock Options (Right to Buy) $47.6 (1) 08/07/2026 Common Stock 186,068 186,068 D
Stock Options (Right to Buy) $66.97 (1) 08/05/2027 Common Stock 167,328 167,328 D
Stock Options (Right to Buy) $120.46 (2) 08/06/2028 Common Stock 40,536 40,536 D
Performance Restricted Stock Units (3) (4) (4) Common Stock 10,912 10,912 D
Performance Stock Options (Right to Buy) $94.52 (4) 08/15/2029 Common Stock 33,916 33,916 D
Stock Options (Right to Buy) $94.52 (5) 08/15/2029 Common Stock 45,220 45,220 D
Performance Restricted Stock Units (3) (6) (6) Common Stock 13,865 13,865 D
Performance Stock Options (Right to Buy) $84.61 (6) 08/15/2030 Common Stock 37,314 37,314 D
Stock Options (Right to Buy) $84.61 (7) 08/15/2030 Common Stock 45,923 45,923 D
Restricted Stock Units (3) (8) (8) Common Stock 13,159 13,159 D
Performance Restricted Stock Units (3) (9) (9) Common Stock 24,062 24,062 D
Restricted Stock Units (3) (10) (10) Common Stock 12,031 12,031 D
Stock Options (Right to Buy) $74.91 (11) 08/15/2034 Common Stock 32,417 32,417 D
Restricted Stock Units (3) (12) (12) Common Stock 34,634 34,634 D
Explanation of Responses:
1. Fully exercisable.
2. Options to purchase 10,134 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.
3. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
4. Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
5. Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
6. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
7. Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
8. 13,159 restricted stock units vest on 11/1/2025.
9. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
10. 4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027.
11. Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
12. 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
/s/ Andrew Nick as Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed 07/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How many TMUS shares did Callie R. Field sell?

She disposed of 12,300 common shares on 07/29/2025.

At what price were the TMUS shares sold?

The weighted-average sale price was $240.80, with trades ranging from $240.79 to $240.87.

How many TMUS shares does Callie R. Field still own after the sale?

She now directly owns 110,891.114 shares.

Was a Rule 10b5-1 trading plan disclosed for this sale?

The form does not indicate that the transaction was executed under a Rule 10b5-1(c) trading plan.

Does this Form 4 include any derivative security transactions?

No; Table II shows no activity in derivative securities.
Stock TECH logo
Bio-Techne Corp

NASDAQ:TECH

TECH Rankings

#1263 Ranked by Market Cap
#1961 Ranked by Dividends

TECH Latest News

Jul 31, 2025
ScaleReady announces multiple G-Rex庐 Grants have been awarded to investigators at University of Minnesota's Center for Genome Engineering
Jul 17, 2025
Bio-Techne to Host Conference Call on August 6, 2025, to Announce Fourth Quarter and Fiscal 2025 Financial Results
Jul 15, 2025
Spear Bio Announces Strategic Partnership with Bio-Techne to Accelerate the Deployment of Its Next-Generation Immunoassay Technology
Jul 15, 2025
Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection
Jul 14, 2025
Bio-Techne's Simple Western鈩� Technology Utilized in Recent FDA Approval of ZEVASKYN鈩� Cell-Based Gene Therapy

TECH Latest SEC Filings

Jul 24, 2025
[Form 4] Bio-Techne Corp. Insider Trading Activity
Jul 17, 2025
[Form 4] Bio-Techne Corp. Insider Trading Activity

TECH Stock Data

9.05B
155.09M
1.05%
101.12%
3.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
MINNEAPOLIS